New strategy aims to save transplant surgeries during COVID-19 infections
NCT ID NCT07197164
Summary
This study is testing whether a 10-day course of the antiviral drug remdesivir can safely prevent kidney transplant patients with mild or no COVID-19 symptoms from developing severe illness. The goal is to allow transplants to proceed without delay for these patients, who are at higher risk. Researchers will give remdesivir to 15 participants starting just before their transplant surgery and monitor them for severe COVID-19 and other health outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Universitari Germans Trias i Pujol
RECRUITINGBadalona, Barcelona, 08916, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.